Abstract
Background
Fibrinolytic therapy for acute ST-elevation myocardial infarction (STEMI) is frequently limited by delays in administration and by incomplete reperfusion or reocclusion of the infarct-related artery. Intensified prehospital management of STEMI may shorten time to treatment and improve outcomes.
Methods
We carried out a prospective substudy in 11 ambulance systems in 216 of the 3,491 patients with STEMI who were enrolled in the CLARITY-TIMI 28 trial. They were randomized in the ambulance to clopidogrel (n = 109) or placebo (n = 107) along with fibrinolysis, aspirin, and heparin. The primary endpoint was the composite of an occluded infarct-related artery (TIMI flow grade 0 or 1), or death or recurrent myocardial infarction before angiography.
Results
All patients received a fibrin-specific lytic and the baseline characteristics in both groups were comparable. The incidence of the primary endpoint was 16.5% in the clopidogrel-treated and 27.1% in the placebo patients (adj OR 0.62, 95% CI 0.31–1.21, p = 0.16), an effect that was consistent with the effects seen in the in-hospital patients in the main CLARITY-TIMI 28 trial. Prehospital clopidogrel therapy reduced the incidence of an occluded infarct-related artery on the predischarge angiogram (11.8% vs. 22.3%, adj OR 0.52, 95% CI 0.24–1.13, p = 0.10). The 30-day incidence of cardiovascular death, recurrent MI or recurrent myocardial ischemia requiring urgent revascularization was 12.8% vs. 14.0% (adj OR 1.07, 95% CI 0.48–2.39, p = 0.87). Early TIMI major bleeding occurred in no clopidogrel patients compared with two placebo patients (1.9%).
Conclusions
Addition of clopidogrel to medical reperfusion of STEMI with fibrinolysis, heparin, and aspirin before reaching the hospital is feasible in medically equipped ambulances without an apparent increase in bleeding. Furthermore, prehospital clopidogrel tended to show better early coronary patency compared to placebo, a result consistent with that observed in patients randomized in-hospital in the CLARITY-TIMI 28 trial.
Similar content being viewed by others
References
Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ (2000) Mortality and prehospital thrombolysis for acute myocardial infarction. JAMA 283:2686–2692
Keeley EC, Boura JA, Grines CL (2003) Primary coronary angioplasty versus intravenous fibrinolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361:13–20
Bonnefoy E, Lapostolle F, Leizorovicz A et al (2002) Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction. Lancet 360:825–829
Van de Werf F, Adgey AAJ, Armstrong PW et al (2001) Efficacy and safety of tenecteplase with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358:605–613
Verheugt FWA, Meijer A, Lagrand WK, Van Eenige MJ (1996) Reocclusion, the flipside of coronary thrombolysis. J Am Coll Cardiol 27:766–773
Brouwer MA, Van den Bergh PJPC, Vromans RP et al (2002) Aspirin plus medium intensity coumadin versus aspirin alone in the prevention of reocclusion after successful thrombolysis for suspected acute myocardial infarction: results of the APRICOT-2 study. Circulation 106:659–665
Ross AM, Molhoek P, Lundergan C et al (2001) Randomized comparison of enoxaparin, a low molecular weight heparin, with unfractionated heparin adjunctive to tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104:648–652
Coussement PK, Bassand JP, Convens C et al (2001) A synthetic factor-Xa inhibitor (ORG13540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE-study. Eur Heart J 22:1716–1724
Simoons ML, Alonso A, Krzeminska-Pakula M et al (2002) Early ST segment elevation resolution: predictor of outcome and angiographic patency in patients with acute myocardial infarction. Results of the AMI-SK study. Eur Heart J 23:1282–1290
Van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360:109–113
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347:969–974
Wallentin L, Wilcox RG, Weaver WD et al (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362:789–797
Sabatine M, Cannon CP, Gibson CM et al (2005) Fibrinolysis with double antiplatelet therapy in ST-elevation acute coronary syndromes. N Engl J Med 352:1179–1189
Wallentin L, Goldstein P, Armstrong PW et al (2003) Efficacy and safety of tenecteplase in combination with the low-molecular weight heparin enoxaparin, or unfractionated heparin in the pre-hospital setting: the ASSENT-3 PLUS randomized trial in acute myocardial infarction. Circulation 108:135–142
Montalescot G, Barragan P, Wittenberg O et al (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895–1903
Montalescot G (2002) GP IIb/IIIa inhibition in primary stenting: do it early, make it easy. Eur Heart J 23:259–260
Lee DP, Herity NA, Hiatt BL et al (2003) Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Angioplasty (TIGER-PA) pilot trial. Circulation 107:1497–1501
Montalescot G, Borentain M, Payot L, Collet JP, Thomas D (2004) Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 292:362–366
Verheugt FWA (2003) Combining glycoprotein blockers with fibrinolysis: a bold stroke? Eur Heart J 24:1801–1803
Chen ZM, Jiang LX, Chen Y et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 366:1607–1621
Metha SR, Eikelboom JW, Yusuf S (2000) Risk of intracranial hemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet 356:449–454
Meijer A, Verheugt FWA, Werter CJPJ, Lie KI, Van der Pol JMJ, Van Eenige MJ (1993) Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation 87:1524–1530
GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 329:1615–1622
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verheugt, F.W.A., Montalescot, G., Sabatine, M.S. et al. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis 23, 173–179 (2007). https://doi.org/10.1007/s11239-006-9047-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-006-9047-y